Latigo Biotherapeutics, Inc.
LTGO
IPO
$22.68
-$0.12-0.53%
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Net Income | -25.80M | -22.96M | -25.84M | ||
| Total Depreciation and Amortization | 52.00K | 47.00K | 66.00K | ||
| Total Amortization of Deferred Charges | 275.00K | -- | -- | ||
| Total Other Non-Cash Items | 2.30M | 2.10M | 2.70M | ||
| Change in Net Operating Assets | 1.89M | -6.26M | 1.51M | ||
| Cash from Operations | -21.28M | -27.07M | -21.56M | ||
| Capital Expenditure | -110.00K | -- | -33.00K | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -110.00K | -- | -33.00K | ||
| Total Debt Issued | 35.00M | -- | -- | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | 153.00K | 78.00K | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -1.00K | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -974.00K | -308.00K | -- | ||
| Cash from Financing | 34.18M | -230.00K | -1.00K | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | 12.79M | -27.30M | -21.59M | ||